151 related articles for article (PubMed ID: 30719604)
1. Suspected adverse effects after human papillomavirus vaccination: a temporal relationship.
Ikeda SI; Hineno A; Ozawa K; Kinoshita T
Immunol Res; 2018 Dec; 66(6):723-725. PubMed ID: 30719604
[TBL] [Abstract][Full Text] [Related]
2. Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan.
Ozawa K; Hineno A; Kinoshita T; Ishihara S; Ikeda SI
Drug Saf; 2017 Dec; 40(12):1219-1229. PubMed ID: 28744844
[TBL] [Abstract][Full Text] [Related]
3. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
[TBL] [Abstract][Full Text] [Related]
4. A Long-Term Observation on the Possible Adverse Effects in Japanese Adolescent Girls after Human Papillomavirus Vaccination.
Hineno A; Ikeda SI
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34451981
[TBL] [Abstract][Full Text] [Related]
5. Autonomic dysfunction and HPV immunization: an overview.
Blitshteyn S; Brinth L; Hendrickson JE; Martinez-Lavin M
Immunol Res; 2018 Dec; 66(6):744-754. PubMed ID: 30478703
[TBL] [Abstract][Full Text] [Related]
6. Compensation programs after withdrawal of the recommendation for HPV vaccine in Japan.
Yuji K; Nakada H
Hum Vaccin Immunother; 2016 May; 12(5):1321-4. PubMed ID: 26513303
[TBL] [Abstract][Full Text] [Related]
7. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
8. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study.
Suzuki S; Hosono A
Papillomavirus Res; 2018 Jun; 5():96-103. PubMed ID: 29481964
[TBL] [Abstract][Full Text] [Related]
9. A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017.
Ward D; Thorsen NM; Frisch M; Valentiner-Branth P; Mølbak K; Hviid A
Euro Surveill; 2019 May; 24(19):. PubMed ID: 31088598
[TBL] [Abstract][Full Text] [Related]
10. The controversy on HPV vaccination in Japan: Criticism of the ethical validity of the arguments for the suspension of the proactive recommendation.
Okita T; Enzo A; Kadooka Y; Tanaka M; Asai A
Health Policy; 2020 Feb; 124(2):199-204. PubMed ID: 31924344
[TBL] [Abstract][Full Text] [Related]
11. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.
Arana J; Mba-Jonas A; Jankosky C; Lewis P; Moro PL; Shimabukuro TT; Cano M
J Adolesc Health; 2017 Nov; 61(5):577-582. PubMed ID: 29061232
[TBL] [Abstract][Full Text] [Related]
12. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
[TBL] [Abstract][Full Text] [Related]
13. Adverse events following HPV vaccination, Alberta 2006-2014.
Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
[TBL] [Abstract][Full Text] [Related]
14. A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan.
Fukushima W; Hara M; Kitamura Y; Shibata M; Ugawa Y; Hirata K; Oka A; Miyamoto S; Kusunoki S; Kuwabara S; Hashimoto S; Sobue T
J Epidemiol; 2022 Jan; 32(1):34-43. PubMed ID: 34719583
[TBL] [Abstract][Full Text] [Related]
15. Survey of Japanese mothers of daughters eligible for human papillomavirus vaccination on attitudes about media reports of adverse events and the suspension of governmental recommendation for vaccination.
Egawa-Takata T; Ueda Y; Morimoto A; Yoshino K; Kimura T; Nishikawa N; Sekine M; Horikoshi Y; Takagi T; Enomoto T
J Obstet Gynaecol Res; 2015 Dec; 41(12):1965-71. PubMed ID: 26420072
[TBL] [Abstract][Full Text] [Related]
16. Examining determinants for reporting suspected adverse events following HPV vaccination in Denmark.
Ulendorf Jacobsen S; Valentiner-Branth P; Mølbak K
Vaccine; 2018 Oct; 36(41):6158-6162. PubMed ID: 30201304
[TBL] [Abstract][Full Text] [Related]
17. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase
Chandler RE; Juhlin K; Fransson J; Caster O; Edwards IR; Norén GN
Drug Saf; 2017 Jan; 40(1):81-90. PubMed ID: 27638661
[TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F
Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799
[TBL] [Abstract][Full Text] [Related]
19. On the contextual nature of vaccine safety monitoring: Adverse events reporting after HPV-vaccination in Denmark, 2015.
Schartau S; Heering Holt D; Lützen T; Rytter D; Mølbak K
Vaccine; 2019 May; 37(19):2580-2585. PubMed ID: 30967312
[TBL] [Abstract][Full Text] [Related]
20. Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data.
Huygen F; Verschueren K; McCabe C; Stegmann JU; Zima J; Mahaux O; Van Holle L; Angelo MG
EBioMedicine; 2015 Sep; 2(9):1114-21. PubMed ID: 26501109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
